Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)

- Featured Image

Important therapeutic advances have been made in the field of cancer immunotherapy in recent years. In particular, immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape of advanced cancer over the past 5 years, with 15–20% of patients achieving long term disease control beyond 5 years.1 ICIs are monoclonal antibodies which block cell surface molecules involved in the regulation of T cell activation, including cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand (PD-L1). In normal homoeostasis, these inhibitory molecules are involved in preventing excessive inflammation and autoimmunity.2 However, in the tumour microenvironment, these molecules are overexpressed and promote immune tolerance rather than tumour destruction.3 Blockade of these molecules can restore the appropriate anti-tumour response and potentially improve patient survival (Box 1). Other inhibitory and activating molecules are also involved in balancing T cell regulation, some of which are undergoing further research as therapeutic targets.24

ICIs with Pharmaceutical Benefits Scheme funding for use in Australia currently include ipilimumab (an anti-CTLA-4 antibody), nivolumab and pembrolizumab…

email